USPTO Memo Cuts Mayo Woes On Treatment Method Patents
Law360 (June 14, 2018, 8:36 PM EDT) -- New guidance from the U.S. Patent and Trademark Office suggests that patents on methods of treating disease should usually be considered patent-eligible, freeing patent holders from having to grapple with the convoluted eligibility analysis patents must often face, attorneys say.
The patent office put out a memo to examiners last week explaining how they should apply an April ruling by the Federal Circuit that a patent covering Vanda Pharmaceuticals Inc.'s schizophrenia drug Fanapt is eligible for patenting under the U.S. Supreme Court's Mayo test.
The office said that when patents cover treatment methods that involve practical applications of natural relationships, like...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!